Spring is not **, summer is sad!
Many friends who are anxious have begun to work on ** matters.
In addition, Jia Ling's self-directed and self-starred movie "Hot and Hot" is currently being screened, which can be said to have ignited the public's enthusiasm all of a sudden.
Although Jia Ling emphasized many times in interviews that the theme of the movie is "love yourself" instead of **, her huge changes still make "** a hot spot at the moment."
It is reported that the secret of Jia Ling's weight loss is to control her diet + strengthen exercise, but it is obvious that this method is difficult for most people to adhere to for a long time, and the effect is naturally needless to say.
So,** Medicine is hot again and has become the object of people's pursuit.
And this popularity has also spread to the A** field, and the concept of "* medicine" is popular again, such as Boji Pharmaceutical, Baihua Pharmaceutical, Changshan Pharmaceutical, Jinkai Biotech, Hanyu Pharmaceutical, etc.
Of course, the reason why the concept of "* medicine" can soar is that hype is not the most critical factorThe stimulation of foreign pharmaceutical giants and the release of domestic and foreign orders are the top priorities.
It is understood that the Danish pharmaceutical giant Novo Nordisk will expand the production of "the best miracle drug" and will acquire the American biopharmaceutical company Catalent for $11.5 billion.
And the reason why Novo Nordisk made such a move is naturally because of the "best medicine" - Wegovy has brought huge benefits to the company, relevant data show thatThe product achieved sales revenue of 313 last yearDKK 4.3 billion, up more than 406% year-on-year.
This is still in the case of Novo Nordisk's limited production capacity, and it is conceivable how much people's demand for first-class drugs is.
In our country, for example, the total number of obese people has reached a staggering 23.8 billion, with an obesity rate of 168%, which is higher than most diseases.
This is true at home, let alone abroad.
The World Obesity Federation (WOF) predictsBy 2035, more than 4 billion people – more than half of the world's population – could be suffering from varying degrees of obesity.
In this context, as a practical solution, "* medicine" will attract a large number of consumers to buy, it can be said that ** medicine is the most certain track at present.
In this regard, after in-depth analysis, Zhuqing selected several potential leaders of "first-class medicine", especially the last one, which is expected to become the next "Tonghua Golden Horse"!
The first, Changshan Pharmaceutical
The company's ebenatid and semaglutide are both GLP-1 drugs. Ebenatide is a long-acting GLP-1 preparation formed by chemically modifying exenatide and combining it with recombinant human albumin using drug affinity conjugate (DACTM) technology. At present, the phase III clinical trial of ebenatitide has all the subjects out of the group.
The second, East China Medicine
As the first approved GLP-1 class ** drug in Chinese mainland, the company's liraglutide injection will meet the drug options of more obese and overweight patients.
The third, Sirnaomics Biology
The company is a peptide API and CDMO R&D and production outsourcing enterprise, one of its main businesses, peptide CDMO services have had obvious growth and breakthroughs, not only involving first-class drugs, but also other peptide drug fields.
The fourth, Tonghua Dongbao
In terms of GLP-1, in addition to semaglutide, the company's products under development include liraglutide, a class of innovative drugs GLP-1 small molecule (THDBH110 111) and GLP-1 GIP dual receptor agonist (THDBH121 for injection).
Fifth, 3***
1. The first leader of innovative drugs + first-class drugs + intelligent medical treatment, the company's product quality has been widely recognized by the market, and many varieties have benefited from the adjustment of the medical insurance catalog.
2. After nearly three months of full adjustment, the company's stock price is at a historical low, the chips are highly concentrated, and the main funds have continued to flow into the net in recent days, and it has been investigated by more than 200 institutions, and the future is promising.
Risk Warning: The views mentioned in this article only represent personal opinions, and the subject matter involved is not recommended.